GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (LTS:0H8T) » Definitions » Cyclically Adjusted Book per Share

Aclaris Therapeutics (LTS:0H8T) Cyclically Adjusted Book per Share : $3.87 (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Aclaris Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Aclaris Therapeutics's adjusted book value per share for the three months ended in Sep. 2024 was $1.824. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.87 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-11-10), Aclaris Therapeutics's current stock price is $2.63. Aclaris Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 was $3.87. Aclaris Therapeutics's Cyclically Adjusted PB Ratio of today is 0.68.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Aclaris Therapeutics was 0.67. The lowest was 0.24. And the median was 0.30.


Aclaris Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Aclaris Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclaris Therapeutics Cyclically Adjusted Book per Share Chart

Aclaris Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 3.86

Aclaris Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 3.86 4.02 4.13 3.87

Competitive Comparison of Aclaris Therapeutics's Cyclically Adjusted Book per Share

For the Diagnostics & Research subindustry, Aclaris Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aclaris Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aclaris Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's Cyclically Adjusted PB Ratio falls into.



Aclaris Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aclaris Therapeutics's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book= Book Value per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=1.824/133.0289*133.0289
=1.824

Current CPI (Sep. 2024) = 133.0289.

Aclaris Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201412 -1.948 99.070 -2.616
201503 0.000 99.621 0.000
201506 0.556 100.684 0.735
201509 -1.964 100.392 -2.602
201512 4.590 99.792 6.119
201603 4.096 100.470 5.423
201606 4.216 101.688 5.515
201609 3.787 101.861 4.946
201612 6.504 101.863 8.494
201703 6.142 102.862 7.943
201706 6.289 103.349 8.095
201709 7.922 104.136 10.120
201712 7.300 104.011 9.337
201803 6.487 105.290 8.196
201806 5.626 106.317 7.040
201809 4.722 106.507 5.898
201812 5.220 105.998 6.551
201903 4.416 107.251 5.477
201906 3.324 108.070 4.092
201909 2.061 108.329 2.531
201912 1.685 108.420 2.067
202003 1.402 108.902 1.713
202006 1.156 108.767 1.414
202009 0.950 109.815 1.151
202012 0.835 109.897 1.011
202103 2.156 111.754 2.566
202106 3.820 114.631 4.433
202109 3.537 115.734 4.066
202112 3.223 117.630 3.645
202203 2.919 121.301 3.201
202206 3.536 125.017 3.763
202209 3.297 125.227 3.502
202212 2.963 125.222 3.148
202303 2.631 127.348 2.748
202306 2.540 128.729 2.625
202309 2.208 129.860 2.262
202312 2.217 129.419 2.279
202403 1.993 131.776 2.012
202406 1.876 132.554 1.883
202409 1.824 133.029 1.824

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Aclaris Therapeutics  (LTS:0H8T) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Aclaris Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.63/3.87
=0.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Aclaris Therapeutics was 0.67. The lowest was 0.24. And the median was 0.30.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Aclaris Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Aclaris Therapeutics Business Description

Traded in Other Exchanges
Address
701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Aclaris Therapeutics Headlines

No Headlines